The 8-week study, performed at the WHO Collaborative Center for Prevention of CVD, the Barzilai Medical Center Ashkelon, Israel, demonstrated that 15-minutes daily self treatment with the Resperate device significantly reduced the blood pressure of patients who were not achieving goal blood pressure despite taking 3 or more antihypertensive drugs at maximum dosage.

The results of the American Journal of Hypertension study are consistent with outcomes reported in six previous peer-reviewed, published studies examining the effects of the device in the general uncontrolled hypertensive patient population and a recent mechanism-of-action review published in the American Heart Association's textbook, Hypertension Primer in May, 2003.

"These are evidence of the effectiveness of Resperate as an adjunctive treatment for hypertension" said Dr. Reuven Viskoper, the principal investigator and the past president of the Israeli Society of Hypertension. "The fact that this non-drug treatment delivered the same significant blood pressure reductions even in refractory hypertensives is clinically meaningful as it provides us with a much needed effective, and side-effect-free treatment option for this patient population".

'"/>

Contact: Tom Kirwan
tkirwan@intercure.com
201-720-7750 ext. 7136
InterCure
30-Jun-2003